Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRD induction in newly diagnosed multiple myeloma
ChiCTR2000030792Phase 4Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Very Good Partial Response. Started Mar 2020; status: recruiting.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2000030792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030792.